Leandro Buffoni Roque da Silva

Dr. Leandro Buffoni Roque da Silva

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
AFAline Luiza Duarte de Freitas
Aline Luiza Duarte de Freitas
VKVanessa Kaplum
Vanessa Kaplum
DRDiego Rossi
Diego Rossi
LSLeandro Buffoni Roque da Silva
Leandro Buffoni Roque da Silva
MMMarcia de Souza Carvalho Melhem
Marcia de Souza Carvalho Melhem
KIKelly Ishida
Kelly Ishida

25 July 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
LSLeandro Buffoni Roque da Silva
Leandro Buffoni Roque da Silva
Carlos TabordaCarlos Taborda
Carlos Taborda
Joshua D NosanchukJoshua D Nosanchuk
Joshua D Nosanchuk
Vaccination is one of the greatest public health achievements in the past century, protecting and improving the quality of life of the population worldwide. However, a safe and effective vaccine for therapeutic or prophylactic treatment of fungal infections is not yet available. The lack of a vaccine for fungi is a problem of increasing importance as the incidence of diverse species, including Paracoccidioides, Aspergillus, Candida, Sporothrix, and Coccidioides, has increased in recent decades and new drug-resistant pathogenic fungi are emerging. In fact, our antifungal armamentarium too frequently fails to effectively control or cure mycoses, leading to high rates of mortality and morbidity. With this in mind, many groups are working towards identifying effective and safe vaccines for fungal pathogens, with a particular focus of generating vaccines that will work in individuals with compromised immunity who bear the major burden of infections from these microbes. In this review, we detail advances in the development of vaccines for pathogenic fungi, and highlight new methodologies using immunoproteomic techniques and bioinformatic tools that have led to new vaccine formulations, like peptide-based vaccines.

2 September 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
SJSamuel Rodrigues Dos Santos Júnior
Samuel Rodrigues Dos Santos Júnior
FSFrancenya Kelley Lopes da Silva
Francenya Kelley Lopes da Silva
LDLucas dos Santos Dias
Lucas dos Santos Dias
ASAna Camila Oliveira Souza
Ana Camila Oliveira Souza
Marcelo AraújoMarcelo Araújo
Marcelo Araújo
Carlos TabordaCarlos Taborda
Carlos Taborda
Paracoccidioidomycosis (PCM) is a granulomatous fungal disease caused by the dimorphic fungal species of Paracoccidioides, which mainly affects the lungs. Modern strategies for the treatment and/or prevention of PCM are based on a Th1-type immune response, which is important for controlling the disease. One of the most studied candidates for a vaccine is the P10 peptide, derived from the 43 kDa glycoprotein of Paracoccidioides brasiliensis. In order to improve its immune modulatory effect, the P10 peptide was associated with a chitosan-conjugated nanoparticle. The nanoparticles presented 220 nm medium size, poly dispersion index (PDI) below 0.5, zeta potential of +20 mV and encapsulation efficiency around 90%. The nanoparticles’ non-toxicity was verified by hemolytic test and cell viability using murine macrophages. The nanoparticles were stable and presented physicochemical characteristics desirable for biological applications, reducing the fungal load and the usual standard concentration of the peptide from 4 to 20 times.

31 July 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
LSLeandro Buffoni Roque da Silva
Leandro Buffoni Roque da Silva
CTCleison L. Taira
Cleison L. Taira
LDLucas dos Santos Dias
Lucas dos Santos Dias
ASAna Camila Oliveira Souza
Ana Camila Oliveira Souza
Joshua D NosanchukJoshua D Nosanchuk
Joshua D Nosanchuk
Carlos TabordaCarlos Taborda
Carlos Taborda
Paracoccidioidomycosis (PCM) is an endemic mycosis in Latin American caused by the thermodimorphic fungi of the genus Paracoccidioides spp. Notably, a Th1 immune response is required to control PCM. In this context, dendritic cells (DCs) seem to be essential players in capture, processing and presentation of Paracoccidioides antigens to naïve T cells and their further activation. We have previously demonstrated that differentiated DCs from bone marrow cells, pulsed with the immunoprotective peptide 10 (P10), effectively control experimental PCM immunocompetent and immunosuppressed mice. However, this procedure may not be infeasible or it is limited for the therapy of human patients. Therefore, we have sought a less invasive but equally effective approach that would better mimics the autologous transplant of DC in a human patient. Here, we isolated and generated monocyte differentiated dendritic cells (MoDCs) from infected mice, pulsed them with P-10, and used them in the therapy of PCM in syngeneic mice. Similar to the results using BMDCs, the P10-pulsed MoDCs stimulated the proliferation of CD4+ T lymphocytes, induced a mixed production of Th1/Th2 cytokines and decreased the fungal burden in murine lungs in the setting of PCM. The process of differentiating MoDCs derived from an infected host, and subsequently used for therapy of PCM is much simpler than that for obtaining BMDCs, and represents a more reasonable approach to treat patients infected with Paracoccidioides. The results presented suggest that P10-primed MoDC may be a promising strategy to combat complicated PCM as well as to significantly shorten the lengthy requirements for treatment of patients with this fungal disease.

7 May 2021 in Future Microbiology
Verified
Journal Article
Closed access
RARodrigo Almeida-Paes
Rodrigo Almeida-Paes
MFMaria Helena Figueiredo-Carvalho
Maria Helena Figueiredo-Carvalho
LSLeandro Buffoni Roque da Silva
Leandro Buffoni Roque da Silva
GGGary Gerfen
Gary Gerfen
GAGlauber Ribeiro de Sousa Araujo
Glauber Ribeiro de Sousa Araujo
Joshua D NosanchukJoshua D Nosanchuk
Joshua D Nosanchuk
Aim: Melanin has been linked to pathogenesis in several fungi. They often produce melanin-like pigments in the presence of L-dihydroxyphenylalanine (L-DOPA), but this is poorly studied in Candida g... Aim: Melanin is a pigment that can help fungi to cause disease. Fungi often produce melanin-like pigments in the presence of L-dihydroxyphenylalanine (L-DOPA), but this is poorly studied in Candida...

25 January 2023 in Fungal Biology
Verified
Journal Article
Closed access
SLSichen Liu
Sichen Liu
DZDaniel Zamith-Miranda
Daniel Zamith-Miranda
RARodrigo Almeida-Paes
Rodrigo Almeida-Paes
LSLeandro Buffoni Roque da Silva
Leandro Buffoni Roque da Silva
PNParimala Nacharaju
Parimala Nacharaju
Joshua D NosanchukJoshua D Nosanchuk
Joshua D Nosanchuk